TOKYO, May 08 (Pulse News Wire) – Prism Biolab Co.,ltd (206A.T) announced today that it received notification of a patent determination for its PepMetics® technology in the United States. The patent application number is 18/14,556, titled "NOVEL HETEROCYCLIC COMPOUNDS." This latest patent determination follows the company's previous announcement on June 09, 2025, concerning the acquisition of patents for its library compounds based on novel molecular frameworks.
With this decision, PRISM BioLab now holds strengthened intellectual property rights in the U.S., similar to those secured in Japan. The company plans to continue pursuing patents in key overseas markets to further drive business growth. According to PRISM BioLab, there will be no impact on its fiscal year ending December 2026 (October 01, 2025 to September 30, 2026).
However, securing these rights in the U.S. is expected to enhance the exclusivity and competitiveness of its compound space, contributing positively to the company’s long-term value. --- PRISM BioLab specializes in developing low-molecular-weight compounds to control protein-protein interactions (PPI) using its proprietary α-helix and β-turn mimicking technology, known as PepMetics®.
The company has established a clinical pipeline in cancer and fibrosis fields and collaborates with major pharmaceutical companies globally to develop innovative treatments for difficult-to-treat diseases.
🟢 Confidence: High AI-translated content.